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Introduction. Advances in hemophilia care and treatment have led to increases in the life expectancy among hemophiliacs. As
a result, persons with hemophilia are reaching an older age and experiencing various age-related health conditions never seen
before in this population. Aim. To determine the prevalence of comorbidities among middle-aged and elderly hemophilia A
and hemophilia B patients. Methods. Retrospective chart review among all hemophilia patients, who attended the Gulf States
Hemophilia and Thrombophilia Center. Results. All patients had at least one comorbid condition other than hemophilia, and the
majority had between 3 and 6 comorbidities. The most common conditions identiﬁed were chronic hepatitis C, hypertension,
HIV, chronic arthropathy, and overweight/obesity. Conclusions. Since persons with comorbidities are more likely to have poorer
health outcomes and require greater care in managing their health needs, caring for aging hemophiliacs is likely to pose various
social and economic challenges for both patients and providers.
1.Introduction
During the past three decades, the life expectancy for indi-
viduals with hemophilia A (a hereditary deﬁciency of coagu-
lation factor VIII) and hemophilia B (a hereditary deﬁciency
of coagulation factor IX) has markedly increased, primarily
due to advances in medical care, as well as the introduction
and availability of clotting factor replacement products and
eﬀective treatments for infectious diseases [1–10]. However,
with this increased longevity and improved quality of life,
comes a generation of middle-aged and elderly hemophiliacs
that are experiencing age-related health conditions that have
subsequently not been seen in this population [1, 6, 10].
Prior to the availability of factorreplacement therapy, the
majority of patients with hemophilia died at an early age
from bleeding problems [2, 4, 11]. Throughout the 1980s
and 1990s, high death rates were observed, due to blood-
borne viral infections, speciﬁcally human immunodeﬁciency
virus (HIV) and the hepatitis C virus (HCV), and replaced
bleeding complications as the primary cause of death
among hemophiliacs [5, 12]. Nevertheless, barring the
increased mortality rates discerned during this period, the
life expectancy for patients with hemophilia, particularly
those with mild or moderate hemophilia, in high and middle
income nations, is currently drawing near to that of the
general male population [13, 14].
While a variety of age-related co-morbidities have been
reported among males in the general population, only
a modest amount of information exists regarding these
new causes of age-related morbidity and mortality and
more speciﬁcally how to deal with these conditions among
individuals with hemophilia [1, 5, 6, 11]. The primary focus
of this study was to identify and estimate the prevalence of
co-morbid conditions that were associated with middle-aged
and elderly hemophilia patients attending at Texas treatment2 Journal of Aging Research
center and evaluate the implications these conditions may
have on future care among individuals in this population.
2.MaterialsandMethods
We conducted a retrospective study among adult patients,
40 years of age or greater, who had a clinical diagnosis of
hemophilia A or hemophilia B, and attended the Gulf States
Hemophilia and Thrombophilia Center (GSHTC) at least
once between January 2007 and August 2010. The GSHTC
is the largest treatment center in the southwest and one of
the largest in the country.
Data were obtained from the patient’s medical charts
using a standardized data abstraction form, and information
regarding the patient’s demographic characteristics, as well
as clinical and co-morbid conditions, was examined. Labo-
ratory ﬁndings, in conjunction with physician notes as well
as medication and problem lists from the patient’s medical
charts, were used to determine whether or not they had
a speciﬁc comorbidity. Furthermore, the diagnostic criteria
usedtodeﬁneindividualco-morbidconditionsaredescribed
in Table 1. Patients who met the inclusion criteria but died
during the speciﬁed observation range were also included
in the study. In addition, we deﬁned comorbidity as the
presence of one or more diseases/conditions, other than the
patient’s hemophilia disease.
Frequency distributions of demographic and treatment-
related characteristics by hemophilia disease were exam-
ined. Diﬀerences between patients with hemophilia A and
hemophiliaBwereassessedusingFischer’sexacttest.Inaddi-
tion, the prevalence of co-morbid conditions was examined
among this patient cohort and compared to that of general
US male population when data were available. All analyses
were conducted using STATA statistical analysis software,
version 11.0 [15].
3. Results
Characteristics of the study sample according to their disease
status are summarized in Table 2. Between January 2007 and
August 2010, the GSHTC saw a total of 404 hemophilia
patients, roughly 16% were 40 years of age or greater. Of the
63 patients who met the inclusion criteria, the majority had
hemophilia A, 71%, respectively. The mean age of the cohort
was approximately 53 years for patients with hemophilia A
and 54 years among patients with hemophilia B. In addition,
themajorityofthesamplevisitedthetreatmentcenterwithin
one year of the observation period was treated on demand
and had mild hemophilia. Patients with hemophilia A and
hemophilia B did not diﬀer signiﬁcantly on any of the
variables examined with the exception of race/ethnicity and
employment status.
Table 3 presents the prevalence of speciﬁc co-morbidities
among the study sample, including comparisons to the age-
matched, general US male population when data were avail-
able. Conﬁdence limits were also estimated in order to draw
comparisons to that of the general US population. However,
due to the small sample size of the study cohort, it is diﬃcult
to draw signiﬁcant comparisons of the representativeness
of the prevalence estimates reported between our patient
population and that of the general US male population. All
patients in the study had at least one co-morbid condition
otherthantheirhemophiliadisease,withthemajorityhaving
between 3 and 6 conditions (mean number of conditions in
the sample was 4). As expected, more than half of the sample
suﬀered from hemophilic arthropathy, 55% of which had
severe hemophilia. Only 21% of the cohort (13 patients) did
not have any blood-borne viral infections: 6% had hepatitis
B virus (HBV) infection, 25% had HIV, 78% had HCV,
25% were coinfected with HIV and HCV, and 5% had both
HBV and HCV. Additionally, diﬀerences in co-morbidities
between hemophilia A and hemophilia B patients were also
examined. While the results did show diﬀerences between
the groups with respect to their HIV, HCV, cardiovascular
disease, renal disease, and arthropathy status, it is diﬃcult to
provide any meaningful statistically signiﬁcant comparisons
due to the small sample size of the study cohort.
A total of 5 patients (8%) died during the study period.
Causes of death included hepatocellular carcinoma (HCC),
acute myeloid leukemia, and lung cancer, and 2 patients died
from accidental, nonmedical factors. Additionally, 5 patients
in the sample, all of whom had hemophilia A (1 patient had
mild hemophilia A, and 4 patients had severe hemophilia
A), received a liver transplant during the observation period.
Among patients receiving a liver transplant, 80% were
diagnosed with end-stage liver disease due to HCV.
Over three-fourths (78%) of the study population had at
least one cardiovascular risk factor including hypertension
(46%), a body mass index (BMI) of 25.0 or higher (65% of
thesamplewasoverweightorobese),highcholesterol(16%),
and diabetes mellitus (14%). In addition, the prevalence of
other co-morbidities that were examined among patients in
this population are reported in Table 2 and include renal
disease (8%), thyroid disease (6%), depression (8%), neuro-
logical disease (5%) including Parkinson’s disease, epilepsy,
and dementia, respiratory disease (11%) including asthma,
sleep apnea, sarcoidosis, and chronic obstructive pulmonary
disease, and gastrointestinal disease (5%) including peptic
ulcer disease and acid reﬂux disease.
4. Discussion
This study revealed a variety of notable diﬀerences with
regard to comparing the prevalence of multiple co-morbid
conditions among middle-aged and elderly hemophilia A
and hemophilia B patients to that of the general US male
population. Previous research has suggested that as much
as 62% of the US population over the age of 65 have more
than one co-morbid condition [21]. Results from this study
indicated that all of the patients in this sample had more
than one co-morbid condition other than their underlying
hemophilia disease, and roughly 19% of the cohort over the
age of 65 had at minimum 3 or more co-morbid conditions.
As noted in previous studies, the prevalence of HIV and
HCVinfectionsareconsiderablyhigheramonghemophiliacs
than in the general male population [4, 5] and are a leading
cause of morbidity and mortality in this population [2, 22,
23]. It is estimated that greater than 90% of hemophiliacsJournal of Aging Research 3
Table 1: Diagnostic criteria for deﬁning co-morbid conditions.
Condition Criteria‡
Human immunodeﬁciency virus HIV-1 PCR quantiﬁcation
On drug therapy (HAART)
Hepatitis C virus HCV RNA
On or received drug therapy
Overweight/obesity
Based on their BMI† score, patients were categorized as overweight or
obese based on the following:
Overweight: 25.0–29.9
Obesity: 30.0 and above
Cardiovascular disease
Echocardiogram ﬁndings
Electrocardiogram ﬁndings
On drug therapy
Cardiologist notes
Hypertension
≥130mmHg systolic blood pressure
≥85mmHg diastolic blood pressure
Primary care physician notes
On drug therapy for elevated blood pressure
Hypercholesterolemia
Lipid proﬁle
On drug therapy for high lipids
Primary care physician notes
Chronic arthropathy Physical ﬁndings
Radiographic ﬁndings
Hepatitis B virus Hepatitis B surface antigen detected for more than 6 months
Diabetes Primary care physician notes
On drug therapy
Renal disease
Patient is on dialysis
Pathology results from biopsy
Estimation of glomerular ﬁltration rate (GFR)
Nephrologist notes
Depression On drug therapy
Psychiatry notes
Respiratory diseases
Positive radiographic ﬁndings
Primary care physician notes
On drug therapy or continuous positive airway pressure (CPAP) therapy
Gastrointestinal diseases
Gastroenterologist notes
Endoscopy ﬁndings
On drug therapy
Thyroid disease On drug therapy
Neurological disease Neurologist or primary care physician notes
On drug therapy
Cancer
Oncologist notes
Pathology reports
Radiographic ﬁndings
‡Patient was considered to have a speciﬁc comorbidity if any of the criteria for that condition was indicated in their chart.
†National Center for Health Statistics. Health, United States, 2009, Hyattsville, MD, 2010.
who were treated with plasma-derived factor concentrates
before 1985 became infected with HCV, and greater than
55% of these patients were also coinfected with HIV [24].
Among patients in this cohort who were between 40 and
49 years of age (N = 29), the prevalence of HIV infection
was approximately 38% compared to 0.74% among age-
matchedmalesintheUS.Inaddition,theprevalenceofHCV
infection in our patient sample was 12 to 90 times higher
than in the age-matched male population (40–49 years: 72%
versus 6%; 50–59 years: 83% versus 1.6%; ≥60 years: 81%4 Journal of Aging Research
Table 2: Selected characteristics of patients 40 years of age or greater, who visited the Gulf States Hemophilia & Thrombophilia Center
between January 1, 2007 and August 31, 2010, according to disease status.
Characteristics Hemophilia A (N = 45) Hemophilia B (N = 18) Total (N = 63)
P value†
n % n % N %
All patients 71.4 28.6
Age in years 0.715
40–49 21 46.6 8 44.5 29 46.0
50–59 14 31.1 4 22.2 18 28.6
60–69 7 15.6 4 22.2 11 17.5
≥70 3 6.7 2 11.1 5 7.9
Race/ethnicity 0.002
Caucasian (non-Hispanic) 26 57.8 8 44.4 34 54.0
Hispanic 16 35.5 2 11.2 18 28.6
African American 3 6.7 8 44.4 11 17.4
Employment status 0.032
Employed full-time 18 40.0 3 16.6 21 33.4
Employed part-time 5 11.1 0 — 5 7.9
Unemployed 22 48.9 14 77.8 36 57.1
Unknown 0— 15 . 611 . 6
Insurance status 0.283
Commercial insurance 18 40.0 8 44.4 26 41.3
Medicare 13 28.9 9 50.0 22 34.9
Medicaid 5 11.1 0 — 5 7.9
State high risk 1 2.2 0 — 1 1.6
Uninsured 8 17.8 1 5.6 9 14.3
Disease severity 0.694
Mild (6%–50%) 23 51.1 9 50.0 32 50.8
Moderate (1%–5%) 6 13.3 4 22.2 10 15.9
Severe (<1%) 16 35.6 5 27.8 21 33.3
Treatment type 0.248
On demand 35 77.8 15 83.3 50 79.4
Intermittent prophylaxis 0— 15 . 611 . 6
Continuous prophylaxis 10 22.2 2 11.1 12 19.0
Last visit to treatment center 0.201
<1 year ago 30 66.7 13 72.2 43 68.3
1-2 years ago 5 11.1 4 22.2 9 14.3
>2 years ago 10 22.2 1 5.6 11 17.4
†Due to small sample sizes, P value for Fischer’s Exact Test is reported.
versus0.9%).Furthermore,chronicHCVinfectionisamajor
risk factor in the development of liver cirrhosis and HCC
[11,25],and,subsequently,HCChasemergedasasigniﬁcant
cause of mortality among HCV-infected hemophiliacs [11].
Roughly 11% of patients in this sample who were diagnosed
with HCV progressed to HCC; one patient died, and more
than half (57%) received a liver transplant. Since the risk
of HCC among HCV-infected hemophilia patients increases
with older ageand the presence of HIV infection [11,22,23],
it is expected that many of the HCV-infected patients in this
sample will progress to end-stage liver disease or HCC.
While cardiovascular disease (CVD) has been the pri-
mary cause of death among individuals in the US for
the past eight decades [26], several studies have reported
that mortality from cardiac events among individuals with
hemophilia is lower than in the general population [7, 8,
13, 27, 28] and hemophilia may actually have a protective
eﬀectagainstCVD[4,11,28].TheprevalenceofCVDamong
patients between 40 and 59 years of age in this study was
similar compared to the age-matched US male population
(40% versus 39%), but slightly lower among those patients
of 60 years of age or greater (69% versus 71%). However,
it should be noted that in order to provide comparisons
between this cohort to that of age-matched males in the US,
patients with CVD were deﬁned as having any of the fol-
lowing conditions (based on the National Center for Health
Statistics deﬁnition): congestive heart disease, heart failure,
stroke, and hypertension. If we excluded hypertension from
the analysis and deﬁned CVD as having only one of the
following conditions: congestive heart disease, heart failure
and/or stroke, the prevalence of CVD among all patients in
the study was approximately 11%.Journal of Aging Research 5
Table 3: Prevalence estimates and 95% conﬁdence intervals of co-morbid conditions among hemophilia patients compared to the general
US male population, by selected characteristics.
Condition
Hemophilia A and B patients (N = 63) Prevalence in general US male population†
n % 95% CI‡ %
Total number of co-morbid
conditions††
1-2 16 25.4 14.35, 36.45
3-4 22 34.9 22.82, 47.02
5-6 17 27.0 15.72, 38.25
≥7 8 12.7 4.24, 21.15
HIV positive 16 25.4 14.35, 36.45 a40–49 years: 0.74
40–49 years 11 37.9 19.15, 56.71
HCV positive 49 77.8 67.22, 88.33
b40–49 years: ∼ 6
50–59: 1.6
≥60 years: 0.9
40–49 years 21 72.4 55.11, 89.72
50–59 years 15 83.3 64.26, 99.02
≥60 years 13 81.3 59.77, 99.03
BMI
Normal (18.5–24.9) 22 34.9 22.82, 47.02
Overweight (25.0–29.9) 25 39.7 27.26, 52.10
Obese (≥30) 16 25.4 14.34, 36.45
BMI ≥25.0 cBMI ≥25.0
40–59 years: 77.8
≥60 years: 78.4
40–59 years 33 70.2 56.64, 83.79
≥60 years 8 50.0 22.48, 77.52
BMI ≥30.0 cBMI ≥30.0
40–59 years: 34.3
≥60 years: 37.1
40–59 years 13 27.7 14.38, 40.93
≥60 years 3 18.8 —
BMI ≥35.0 cBMI ≥35.0
40–59 years: 11.6
≥60 years: 11.6
40–59 years 6 12.8 2.8, 22.67
≥60 years 1 6.3 —
BMI ≥40.0 cBMI ≥40.0
40–59 years: 4.2
≥60 years: 4.2
40–59 years 2 4.3 —
≥60 years — — —
Cardiovascular disease††† 30 47.6 34.94, 60.30 d40–59 years: 39.1
≥60 years: 71.3 40–59 years 19 40.4 25.86, 54.99
≥60 years 11 68.8 43.24, 94.26
Hypertension 29 46.0 33.38, 58.69
40–44 years 6 46.2 14.80, 77.51
e45–54 years: 36.2
55–64 years: 50.2
65–74 years: 64.1
≥75 years: 65.0
45–54 years 7 30.4 10.09, 50.78
55–64 years 8 53.3 24.74, 81.93
65–74 years 6 60.0 23.06, 96.94
≥75 years 2 100 —
Hypercholesterolemia 10 15.9 6.60, 25.15
45–54 years 4 17.4 0.63, 34.15 e45–54 years: 36.2
55–64 years: 50.2
65–74 years: 64.1
≥75 years: 65.0
55–64 years 2 13.3 —
65–74 years 2 20.0 —
≥75 years 1 50.0 —
Chronic arthropathy 33 52.4 39.70, 65.06
40–59 years 22 46.8 32.00, 61.62
≥60 years 11 68.8 43.24, 94.266 Journal of Aging Research
Table 3: Continued.
Condition
Hemophilia A and B patients (N = 63) Prevalence in general US male population†
n % 95% CI‡ %
HBV positive 4 6.4 0.16, 12.54
Diabetes 9 14.3 5.40, 23.17
Renal disease 5 7.9 1.07, 14.80
Depression 5 7.9 1.07, 14.80
Respiratory disease 7 11.1 3.13, 19.09
Gastrointestinal disease 3 4.8 —
Thyroid disease 4 6.4 0.16, 12.54
Neurological disease 3 4.8 —
Cancer 10 15.9 6.60, 25.15
Hepatocellular carcinoma 7 70.0
Non-Hodgkin’s lymphoma 1 10.0
Lung cancer 1 10.0
Leukemia 1 10.0
‡CI: Conﬁdence interval,
†Prevalence estimates reported when data were available:
asee [16].
bsee [17].
csee [18].
dsee [19].
esee [20].
††Number of conditions excluding hemophilia disease.
†††Includes patients with cardiovascular disease, hypertension, and stroke.
Despite conﬂicting reports regarding a possible protec-
tive eﬀect against CVD among individuals with hemophilia
[4, 11, 28], common risk factors for CVD including
hypertension, high cholesterol, diabetes mellitus (DM), and
overweight/obesity were observed among patients in this
study. The prevalence of hypertension was lower compared
to the US population among all age groups except among
patients between 55 and 64 years of age. No diﬀerences
were observed between our patient population and the age-
matched general population with respect to high cholesterol.
Whileover65% ofthis cohortwasoverweightorobese, these
rates were lower compared to the age-matched population.
In addition, overweight and obesity were more prevalent
among patients with mild hemophilia (72%), which is
similar to a ﬁnding reported in a previous study [29].
An increased bodyweight is an important risk factor
associated not only with CVD, but also in the development
of DM and chronic arthropathy. Only a limited amount
of information exists regarding the prevalence of DM
among hemophiliacs. The study conducted by Walsh et al.
[30] estimated that the prevalence of DM among mild
hemophiliacs was 24% compared to 6% in control males
(mean age of subjects in both groups was 46 years of age)
[30].TheprevalenceofDMamongallpatientsinthissample
was 14%, and roughly 89% of those patients who had DM
also had a BMI greater than 25.
The majority of hemophiliacs born prior to the avail-
ability of prophylactic therapy suﬀer from hemophilic
arthropathy [4], which continues to be the primary cause
of morbidity among individuals in this population [2]. As
expected, half of the patients in this cohort suﬀer from
chronic arthropathy, of which 56% had severe hemophilia
and 53% had a BMI of 25 or higher. In addition, overweight
and obesity may have greater implications on persons with
hemophilia due to the fact that an increased bodyweight
may cause additional damage to already deteriorated joints
[29]. Furthermore, since the dosage of factor replacement
treatment is based on bodyweight, the costs of care are much
higher among overweight and obese patients compared with
patients with a normal bodyweight.
Renal disease is another age-related medical condition
that aﬀects hemophiliacs, who are reported to have up to a
50-foldincreaseinmortalityduetorenalfailurecomparedto
the general population [31]. Previous research has indicated
that risk factors for renal failure among individuals with
hemophilia include increased age, hypertension, and HIV
co-infection [1, 32]. Approximately 8% of patients in this
sample had chronic renal disease, 20% of which also had
HIV, and 40% of which had hypertension. With the mean
age of all patients in this cohort being 53 years of age, it is
likely that more cases of renal disease will be observed as the
population continues to age.
While hemophilia care has undergone substantial ad-
vancementsduringthepastthreedecades,avarietyofhealth-
care needs arising from many of the age-related co-mor-
bidities mentioned in this paper pose signiﬁcant chal-
lenges for the treatment and management of these condi-
tions among aging hemophiliacs. Currently, there are few
evidence-based guidelines that direct medical professionals
on how to most eﬀectively manage the comprehensive careJournal of Aging Research 7
needs of hemophilia patients with these age-related co-
morbidities [1, 11]. As a result, optimal treatment and
care for hemophiliacs with multiple co-morbid conditions
has been challenging for both healthcare providers and the
patient.
Further studies are needed to document the safety and
eﬃcacy of certain drug therapies, procedures, and lifestyle
changesamongaginghemophiliacswithmultipleco-morbid
conditions. For example, no explicit guidelines are available
for addressing CVD risk in persons with hemophilia. While
there are modiﬁable lifestyle factors that can be addressed
including diet, exercise, and smoking cessation programs
[11], safety of frequent aspirin use needs to be evaluated
as this could cause an increase in the bleeding frequency
among hemophiliacs. In addition, with regard to lifestyle
f a c t o r ss u c ha se x e r c i s ea n da c t i v i t yp r o g r a m st oh e l p
reduce the risk of CVD as well as other conditions such as
overweight/obesity and diabetes, these may not be practical
and/or may be diﬃcult particularly for patients with chronic
arthropathy. Support from physical therapists at treatment
centersmayplayacriticalroleinpromotinganactivelifestyle
within the boundaries of a patient’s abilities.
Given the complexities associated with how to best care
for and treat hemophiliacs with multiple co-morbid con-
ditions, successful management must entail a multifaceted
approach, which encompasses drawing from expertise not
onlyfromhematology,butthatofcardiology,oncology,urol-
ogy, infectious disease, orthopedics, hepatology, nephrology,
and internal medicine. A lack of coordination between these
various departments may aﬀect the delivery of appropriate
andtimelyhealthcareservices.Hemophiliatreatmentcenters
shouldplayanessentialroleincoordinatingthecareforthese
patients to ensure they are knowledgeable of the services
they need as well as understand the implications associated
with seeking timely care from these services. However,
management and treatment requirements for speciﬁc co-
morbidities need to be an interdisciplinary eﬀort, and
hemophilia treatment centers cannot be the sole caregivers
for hemophiliacs with multiple co-morbidities. As such,
lifestyle issues as well as general screening programs should
be incorporated in the management and treatment plans,
including assistance with timely referrals and followup with
appropriate specialty services for aging hemophilia patients
attending treatment centers.
5. Conclusions
Individuals with multiple co-morbid conditions tend to
receive suboptimal care, which can lead to poorer health
outcomes and increased treatment costs. In addition, the
challenge of providing adequate care increases in complexity
as the number of chronic conditions increases [21, 33],
resulting in disproportionately high health care costs. It
is estimated that over 75% of health care expenditures
in the US are spent on care for persons with multiple
co-morbidities [21] and the average spending per person
with co-morbidities is roughly ﬁve times greater compared
with individuals with no chronic conditions [33]. As the
world population of persons with hemophilia ages, an
increase in age-related health conditions not previously seen
in this population are likely to become more prevalent.
Hemophilia is an already costly disease, and understanding
both treatment care needs and its related costs among aging
hemophiliacswithmultipleco-morbiditiesiscriticalinorder
to provide optimal care and manage their comprehensive
health needs eﬀectively. While this study identiﬁed a variety
of co-morbidities associated with middle-aged and elderly
hemophiliacs, only 63 patients were included in the cohort,
thus making it diﬃcult to provide any statistically signiﬁcant
comparisons. Moreover, due to the small sample size of
the cohort, our estimates of co-morbidities make it diﬃcult
to draw signiﬁcant comparisons between our hemophilia
patient population and the general US male population.
In addition, since patients were classiﬁed as having a
speciﬁc condition based on information available in their
medical charts, the possibility of underestimating certain co-
morbiditiesmaybeofconcern.Furtherresearch,particularly
larger, multicenter, prospective studies are needed to identify
how to best care for and treat aging hemophilia patients with
multiple co-morbidities.
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